Influenza Clinical Trial
Official title:
A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and Associations With the Nasopharyngeal Microbiome Among Children in the Gambia - The NASIMMUNE Study
The live attenuated influenza vaccine (LAIV) is made up of weakened influenza viruses given
into the nose and in early studies was shown to be better than the standard influenza vaccine
at preventing infections in children. However, more recently, it has performed less well and
it may also work less well in Sub-Saharan Africa. Not only do the investigators not know why
this is, but the investigators also do not fully understand why LAIV produces stronger nasal
antibody responses in some individuals but not others. Usually harmless bacteria that are
present in participants noses can influence how our immune system works and variations in
these may explain differences in how LAIV works. The project will recruit children given LAIV
in the Gambia to gain further understanding of these issues.
The investigators will measure a variety of responses to LAIV, including genes that can
change their expression early after vaccination and use advanced computational techniques to
identify new relationships between these genes and other LAIV responses. The investigators
will also see whether nasal bacterial profiles in children who respond to LAIV are different
from those who do not. In addition, the investigators will alter these bacteria in a subset
of children with antibiotics and see whether this affects both nasal gene expression and
later responses to LAIV.
Purpose The overall goal of this study is to conduct at detailed immunogenicity study of
intranasal live attenuated influenza vaccine (LAIV; Nasovac-S, Serum Institute of India Pvt.
Ltd.), including identification of early molecular signatures associated with a robust
mucosal immune response. In addition, the study team will explore whether the nasopharyngeal
microbiome influences this immune response and whether LAIV has an impact on the microbiome.
A total of 365 healthy children aged 24 - 59 months will be recruited in The Gambia for this
study.
Background Both the burden of infection and use of influenza vaccines in children from
sub-Saharan Africa (SSA) have been neglected. There are limited immunogenicity or efficacy
data from SSA of the widely used Ann Arbor strain-derived LAIV. This LAIV was shown to have
greater relative efficacy compared to inactivated influenza vaccine in children in early
randomized-controlled trials. There has, however, been concern regarding lower vaccine
effectiveness in the US in recent years.
The Serum Institute of India Pvt. Ltd. has recently developed a trivalent LAIV (Nasovac-S)
via a WHO facilitated donation of a Russian-derived LAIV, with the intention of scaling up
provision of LAIV to resource-limited settings. Based on initial safety and immunogenicity
data, Nasovac-S was licensed in India and granted a WHO prequalification certificate in 2015.
Two placebo-controlled efficacy studies using Nasovac-S were recently undertaken in
Bangladesh and Senegal (in children aged 24 - 59 months and 24 - 71 months respectively),
providing mixed and contrasting results. In Senegal, no efficacy was found against the
circulating pandemic H1N1 influenza strain (-9.7%, 95% CI -62.6, 26.1). In Bangladesh the
overall vaccine efficacy to vaccine-matched strains, in a study of identical design, was
57.5% (95% CI 43.6, 68.0), with efficacy against H1N1 and H3N2, 50.0% (95% CI 9.2, 72.5) and
60.4% (95% CI 44.8, 71.6) respectively. The reason for the discrepancy in these studies or
the poorer performance of the H1N1 component is not clear and emphasizes the need to
undertake detailed immunogenicity studies of this vaccine in SSA. On a wider note, the exact
immunological mechanisms of action of LAIV are also under-explored.
Study type:
Interventional
Design:
All primary objectives will be addressed through the conduct of a phase 4, randomized,
controlled clinical vaccine trial. A total of 330 healthy children aged 24 - 59 months will
be enrolled into one of three groups of equal size (3 x 110 children):
(i) LAIV-vaccinated (Group A - blood sample at day 0, 2, 21) (ii) LAIV-vaccinated (Group B -
blood sample at day 0, 7, 21) (iii) Control group (Group C)
The study is not blinded, but group allocation will be concealed from the investigator team
and block randomization stratified by sex will be undertaken.
Two LAIV-vaccinated groups are included in order to achieve several exploratory objectives,
which require blood sampling at different times following vaccination, whilst minimizing the
number of times children are bled. The unvaccinated subjects will serve as a control group
for the primary objective of assessing the impact of LAIV on the nasopharyngeal microbiome.
An additional 35 healthy children aged 24 - 59 months will be recruited in the 2nd phase of
recruitment (approximately Jan - June 2018) to assess how modulation of the nasopharyngeal
microbiome with antibiotics impacts the mucosal immunogenicity to LAIV. These subjects will
be matched as closely as possible by pre-antibiotic nasopharyngeal microbiome profile, age
and sex (in that order of preference), in an exploratory nested case-control study, to n = 35
children recruited in the main clinical trial.
Official title A Study of Intranasal Live Attenuated Influenza Vaccine Immunogenicity and
Associations with the Nasopharyngeal Microbiome Among Children in the Gambia (The NASIMMUNE
study)
Primary outcome measures
- To identify novel early systemic and mucosal molecular signatures following LAIV that
are associated with subsequent robust nasal and oral influenza-specific immunoglobulin A
(IgA) responses, in order to provide insight into the mechanisms of successful mucosal
immunization
- To identify associations between nasopharyngeal microbiota and nasal and oral
influenza-specific IgA responses post-LAIV in Gambian children, to explore whether
microbiome variability can explain suboptimal immune responses in some individuals to
live intranasal mucosal vaccines in Sub-Saharan Africa
- To establish whether LAIV impacts the nasopharyngeal microbiome, with a specific focus
on the burden of S. pneumoniae
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
| Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
| Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
| Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
| Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
| Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
| Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
| Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
| Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
| Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
| Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
| Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
| Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
| Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
| Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
| Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
| Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
| Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
| Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |